

VPA10996/285/001

Vecoxan 2.5 mg/ml Oral Suspension for lambs and calves

Variation	Summary	Date
Vet – B24 a)	VNRA - Vet – B24 a) - B24 Replacement or addition of a manufacturer responsible for a) - B24 Replacement or addition of a manufacturer responsible for a)- batch release including batch control or testing of a sterile or non-sterile finished product	08/04/24
Vet - B21	VNRA - Vet - B21 - Replacement or addition of a secondary packaging site of a finished product - B21 Changes to the quality part of the dossier: Replacement or addition of a secondary packaging site of a finished product	08/04/24
Vet - B47 b)	VNRA - Vet - B47 b) - b) Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State - B47 b) Changes to the quality part of the dossier: Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State: — change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State	08/04/24
Vet - B20	VNRA - Vet - B20 - Replacement or addition of a primary packaging site of a non-sterile finished product - B20 Changes to the quality part of the dossier: Replacement or addition of a primary packaging site of a non-sterile finished product	08/04/24
Vet - F.I.b.1 z)	VRA-S - Vet - F.I.b.1 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.I.b.1 z) Quality Changes - Active Substance - Control of active substance -Change in the specification parameters and/or limits of an active substance, starting material/intermediate/reagent used in the manufacturing process of the active substance - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	08/04/24
Vet - F.II.e.2 z)	VRA-S - Vet - F.II.e.2 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.e.2 z) Quality Changes - Container closure system - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	08/04/24
Vet - F.II.e.1 a) 1.	VRA-S - Vet - F.II.e.1 a) 1. - a) Qualitative and quantitative composition 1. Semi-solid and non-sterile liquid pharmaceutical forms - F.II.e.1 a) 1. Quality Changes - Container closure system - Change in immediate packaging of the finished product - Semi-solid and non-sterile liquid pharmaceutical forms	08/04/24
Vet - F.II.d.1 z)	VRA-S - Vet - F.II.d.1 z) - z) Other changes under this code	08/04/24

	level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.d.1 z) Quality Changes - Finished Product -Control of finished product - Change in the specification parameters and/or limits of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	
Vet - F.II.d.2 b)	VRA-S - Vet - F.II.d.2 b) - b) Other changes to a test procedure (including replacement or addition) - F.II.d.2 b) Quality Changes - Finished Product -Control of finished product - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	08/04/24
Vet - F.II.c.1 z)	VRA-S - Vet - F.II.c.1 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.c.1 z) Quality Changes - Finished Product -Control of excipients-Change in the specification parameters and/or limits of an excipient - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	08/04/24
Vet - F.II.b.1 c)	VRA-S - Vet - F.II.b.1 c) - c) Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products - F.II.b.1 c) Quality Changes - Finished Product -Manufacture - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products	08/04/24
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	04/04/24
Vet - B26 a)	VNRA - Vet - B26 a) - a) Up to 10-fold increase compared to the originally approved batch size of an immediate release oral pharmaceutical forms or of a non-sterile liquid based pharmaceutical form - B26 a) Changes to the quality part of the dossier: Change in the batch size (including batch size ranges) of the finished product: — up to 10-fold increase	16/01/24

	compared to the originally approved batch size of an immediate release oral pharmaceutical forms or of a non-sterile liquid based pharmaceutical form	
Vet - B44	VNRA - Vet - B44 - Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile active substance, starting material, reagent or intermediate, excipient - B44 Changes to the quality part of the dossier: Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile: — active substance; — starting material, reagent or intermediate used in the manufacturing process of the active substance; — excipient	16/01/24
C.II.7.b	IB - C.II.7.b - b) Which has been assessed by the relevant national competent authority/EMA for another product of the same MAH(*) - C.II.7.b - SAFETY, EFFICACY, PHARMACOVIGILANCE CHANGES - VETERINARY MEDICINAL PRODUCT ?SPECIFIC CHANGES - Introduction of a new Pharmacovigilance system - Which has been assessed by the relevant national competent authority/EMA for another product of the same MAH(*)	02/02/22